Immunology and Cell Biology, Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA, 92121, USA.
BioDrugs. 2018 Feb;32(1):83-89. doi: 10.1007/s40259-018-0260-y.
Recombinant human PH20 (rHuPH20) is used to depolymerize hyaluronan in the subcutaneous space, increasing the dispersion and absorption of co-administered drugs. While ~ 5 to 10% of rHuPH20 treatment-naïve healthy volunteers have demonstrated rHuPH20-reactive antibodies, associations with age, sex, fertility, and immune disorders remain unknown.
Using demographically diverse healthy volunteers, we assessed the prevalence of rHuPH20-reactive antibodies in the general population and potential associations with fertility and autoimmunity diseases.
In total, 896 subjects aged ≥ 12 years (767 adults; 129 children) without prior exposure to rHuPH20 were enrolled. A demographic and limited medical history review was performed, and K3-EDTA-anticoagulated plasma was analyzed for rHuPH20-reactive antibodies using a bridging immunoassay.
Adult and pediatric positivity rates for rHuPH20-reactive antibodies were 5.2% (40/767) and 1.6% (2/129), respectively. Titers ranged from 5 to 2560 (median 30). In five antibody-positive subjects from whom repeated samples were available, antibody titers remained unchanged or decreased fourfold over periods up to 590 days. The prevalence of rHuPH20-reactive antibodies significantly increased with age (p = 0.0006) and was significantly higher in males than in females (p = 0.0010). Men who had fathered children had a significantly increased prevalence of rHuPH20-reactive antibodies than men who had not (p = 0.0036), whereas the rate of childbearing was not significantly different between rHuPH20 antibody-positive and -negative women. The prevalence between racial/ethnic groups was not significantly different, nor was the presence/absence of an autoimmune disorder.
Approximately 1/20 of the adult population had rHuPH20-reactive antibodies. The reason remains unknown; however, no evidence for a negative effect on fertility or association with autoimmune disease was demonstrated.
重组人 PH20(rHuPH20) 用于分解皮下空间中的透明质酸,增加同时给予的药物的分散和吸收。虽然 ~5%至 10%的 rHuPH20 治疗初治的健康志愿者表现出 rHuPH20 反应性抗体,但与年龄、性别、生育能力和自身免疫性疾病的关联仍不清楚。
使用人口统计学上多样化的健康志愿者,我们评估了 rHuPH20 反应性抗体在普通人群中的流行率,并评估了与生育能力和自身免疫性疾病的潜在关联。
共纳入 896 名年龄≥12 岁(767 名成人;129 名儿童)且无 rHuPH20 暴露史的受试者。进行了人口统计学和有限的病史回顾,并使用桥联免疫分析法分析 K3-EDTA 抗凝血浆中的 rHuPH20 反应性抗体。
成人和儿科 rHuPH20 反应性抗体的阳性率分别为 5.2%(40/767)和 1.6%(2/129),滴度范围为 5 至 2560(中位数 30)。在 5 名可重复获得样本的抗体阳性受试者中,抗体滴度在长达 590 天的时间内保持不变或降低四倍。rHuPH20 反应性抗体的阳性率随年龄显著增加(p=0.0006),男性显著高于女性(p=0.0010)。有生育能力的男性 rHuPH20 反应性抗体的阳性率显著高于无生育能力的男性(p=0.0036),而 rHuPH20 抗体阳性和阴性女性的生育率没有显著差异。不同种族/族裔群体之间的阳性率没有显著差异,自身免疫性疾病的存在与否也没有显著差异。
约 1/20 的成年人口具有 rHuPH20 反应性抗体。原因尚不清楚;然而,没有证据表明对生育能力有负面影响或与自身免疫性疾病有关。